Arbutus Biopharma Corp (ABUS) — Cash Flow-to-Debt Ratio
Arbutus Biopharma Corp (ABUS) has a Cash Flow-to-Debt Ratio of -0.48x as of March 2026, meaning its operating cash flow of $-8.11 Million could theoretically repay 0% of its total liabilities ($16.99 Million) in one year. Explore Arbutus Biopharma Corp long-term investment allocation to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Arbutus Biopharma Corp Cash Flow-to-Debt Ratio (1998–2025)
Historical debt coverage capacity for Arbutus Biopharma Corp across 28 annual periods. Also explore ABUS total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Arbutus Biopharma Corp (1998–2025)
Year-by-year debt coverage analysis for Arbutus Biopharma Corp. For market capitalisation and broader financial context, see Arbutus Biopharma Corp stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.20x | $-39.64 Million | $18.04 Million | ▼ -16.3% |
| 2024 | -1.89x | $-64.85 Million | $34.34 Million | ▲ +15.7% |
| 2023 | -2.24x | $-85.94 Million | $38.38 Million | ▼ -270.9% |
| 2022 | -0.60x | $-35.36 Million | $58.57 Million | ▲ +68.7% |
| 2021 | -1.93x | $-67.53 Million | $35.05 Million | ▼ -31.5% |
| 2020 | -1.46x | $-51.44 Million | $35.11 Million | ▲ +32.3% |
| 2019 | -2.17x | $-71.01 Million | $32.79 Million | ▲ +11.8% |
| 2018 | -2.45x | $-67.90 Million | $27.67 Million | ▼ -176.2% |
| 2017 | -0.89x | $-48.60 Million | $54.70 Million | ▼ -11.9% |
| 2016 | -0.79x | $-57.88 Million | $72.90 Million | ▼ -138.6% |
| 2015 | -0.33x | $-54.78 Million | $164.61 Million | ▲ +19.1% |
| 2014 | -0.41x | $-12.42 Million | $30.20 Million | ▲ +23.6% |
| 2013 | -0.54x | $-6.74 Million | $12.52 Million | ▼ -118.9% |
| 2012 | 2.85x | $33.27 Million | $11.68 Million | ▲ +421.9% |
| 2011 | -0.89x | $-7.52 Million | $8.50 Million | ▲ +19.0% |
| 2010 | -1.09x | $-11.25 Million | $10.29 Million | ▼ -35.8% |
| 2009 | -0.80x | $-5.24 Million | $6.51 Million | ▲ +61.6% |
| 2008 | -2.09x | $-8.48 Million | $4.05 Million | ▼ -397.5% |
| 2007 | -0.42x | $-2.72 Million | $6.46 Million | ▲ +5.7% |
| 2006 | -0.45x | $-2.62 Million | $5.88 Million | ▼ -13.2% |
| 2005 | -0.39x | $-14.57 Million | $36.99 Million | ▼ -103.6% |
| 2004 | -0.19x | $-9.98 Million | $51.60 Million | ▲ +94.7% |
| 2003 | -3.67x | $-26.96 Million | $7.35 Million | ▼ -59.0% |
| 2002 | -2.31x | $-18.16 Million | $7.87 Million | ▼ -41.1% |
| 2001 | -1.64x | $-10.00 Million | $6.12 Million | ▲ +51.2% |
| 2000 | -3.35x | $-8.35 Million | $2.49 Million | ▲ +5.9% |
| 1999 | -3.56x | $-6.84 Million | $1.92 Million | ▲ +35.1% |
| 1998 | -5.49x | $-7.71 Million | $1.40 Million | — |